ArticleFEBS letters2026
Disrupted STIL-BRCA1 axis causes centrosome amplification and genomic instability.
Article in FEBS letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Centrosome abnormalities can lead to erroneous chromosome segregation during cell division, resulting in genomic instability. We identified a cancer-associated heterozygous missense mutation (S76L) in the centrosome protein STIL that promotes centrosome amplification and DNA damage. STIL was found to interact with BRCA1 regulating its stability; this, however, is disrupted by the S76L mutation. Mimicking the heterozygous state by overexpressing STIL-S76L redistributed BRCA1 from the nucleus to centrosomes and elevated centrosomal Aurora-A and PLK1 kinases that are responsible for centrosome amplification. Decreased nuclear BRCA1 in the mutant state induced DNA damage, which was rescued by co-expression of wild-type but not nuclear localization-deficient BRCA1. Despite amplified centrosomes, mutant cells maintain pseudo-bipolar spindle organization via kinesin HSET (KIFC1)-dependent clustering, a known cancer survival mechanism and potential therapeutic target. Together, our findings uncover a previously unrecognized STIL-BRCA1 regulatory axis that safeguards centrosome homeostasis and genome integrity. Impact statement Our study reveals a cancer-associated STIL mutation that disrupts its interaction with BRCA1, thereby destabilizing BRCA1 and leading to centrosome amplification and DNA damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.